Allarity Therapeutics, Inc. has filed an Amendment No. 2 to the Schedule 13G with the U.S. Securities and Exchange Commission (SEC), indicating significant changes in ownership by reporting persons. The amendment, dated September 30, 2024, reflects the aftermath of a 1-for-30 reverse stock split of the company's common stock that occurred on September 9, 2024. The filing was made by three reporting persons: 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, all of whom have ceased to be the beneficial owners of more than five percent of Allarity Therapeutics' outstanding common stock. This amendment serves as an exit filing for each of the reporting persons, marking their departure from a significant ownership position in the company. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013. The filing emphasizes that the shares were not acquired for the purpose of changing or influencing the control of the issuer.

Allarity Therapeutics, Inc. has filed an Amendment No. 2 to the Schedule 13G with the U.S. Securities and Exchange Commission (SEC), indicating significant changes in ownership by reporting persons. The amendment, dated September 30, 2024, reflects the aftermath of a 1-for-30 reverse stock split of the company's common stock that occurred on September 9, 2024. The filing was made by three reporting persons: 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, all of whom have ceased to be the beneficial owners of more than five percent of Allarity Therapeutics' outstanding common stock. This amendment serves as an exit filing for each of the reporting persons, marking their departure from a significant ownership position in the company. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013. The filing emphasizes that the shares were not acquired for the purpose of changing or influencing the control of the issuer.